Source comparison
Bioavailability Data: SubQ vs IM Administration Routes
Bioavailability. The fraction of administered peptide that reaches systemic circulation in active form. Varies significantly between SubQ and IM routes for growth hormone secretagogues. Pharmacokinetic studies measuring serum peptide concentrations at 15-minut
This comparison does not assign a generated winner or score.
- Bioavailability. The fraction of administered peptide that reaches systemic circulation in active form. Varies significantly between SubQ and IM routes for growth hormone secretagogues. Pharmacokinetic studies measuring serum peptide concentrations at 15-minute intervals post-injection consistently demonstrate SubQ administration achieves 82–89% bioavailability for peptides in the 2–5 kDa molecular weight range (which includes both tesamorelin and ipamorelin), while IM injection achieves 68–74% bioavailability.
- The mechanism behind this difference: intramuscular tissue contains higher concentrations of proteolytic enzymes (cathepsins, matrix metalloproteinases) that begin degrading peptide chains before they fully enter circulation. Subcutaneous adipose tissue has lower enzymatic activity and functions primarily as a physical barrier rather than a metabolic one. A 2019 study in Peptides journal found that peptides administered via SubQ route maintained structural integrity 15–22% longer than those delivered IM when measured via mass spectrometry.
- Injection site selection within each route also matters. SubQ injections into abdominal adipose tissue (2–4 inches lateral to the umbilicus) produce the most consistent absorption kinetics due to uniform capillary density and minimal fascial interference. IM injections into the deltoid or vastus lateralis show more variable absorption based on muscle mass, blood flow, and recent physical activity. Factors that don't affect SubQ administration.